Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CESS-GD2: Dinutuximab Beta + VDC/IE in High-Risk Ewing Sarcoma
NCT06839703Phase 1Recruiting
- Start
- May 2025
- Primary completion
- Mar 2027
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of Dinutuximab beta in Ewing sarcoma. Primary endpoints: GD2 Positivity and Dose-Limiting Toxicities. Started May 2025; status: recruiting.
02
Drugs
Dinutuximab beta
03
Conditions
Ewing sarcoma
Beyond the preview
Go deeper on NCT06839703.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06839703.